2020
Use of intravenous magnesium sulfate among patients with acute myocardial infarction in China from 2001 to 2015: China PEACE—Retrospective AMI Study
Wang X, Du X, Yang H, Bucholz E, Downing N, Spertus JA, Masoudi FA, Li J, Guan W, Gao Y, Hu S, Bai X, Krumholz HM, Li X. Use of intravenous magnesium sulfate among patients with acute myocardial infarction in China from 2001 to 2015: China PEACE—Retrospective AMI Study. BMJ Open 2020, 10: e033269. PMID: 32220910, PMCID: PMC7170603, DOI: 10.1136/bmjopen-2019-033269.Peer-Reviewed Original ResearchConceptsIntravenous magnesium sulfateAcute myocardial infarctionMagnesium sulfate useMyocardial infarctionMagnesium sulfateChina PEACE-Retrospective AMI StudyHospital-level variationProportion of hospitalsHospital-specific characteristicsMedian ORsSignificant initial decreaseReperfusion therapyCardiac arrestAMI careIneffective therapyPatient outcomesRepresentative sampleObservational studyMAIN OUTCOMEChinese guidelinesPatientsChinese hospitalsRoutine useAMI studyInfarction
2015
Patterns of Use of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Among Patients With Acute Myocardial Infarction in China From 2001 to 2011: China PEACE‐Retrospective AMI Study
Liu J, Masoudi FA, Spertus JA, Wang Q, Murugiah K, Spatz ES, Li J, Li X, Ross JS, Krumholz HM, Jiang L, Group C. Patterns of Use of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Among Patients With Acute Myocardial Infarction in China From 2001 to 2011: China PEACE‐Retrospective AMI Study. Journal Of The American Heart Association 2015, 4: e001343. PMID: 25713293, PMCID: PMC4345866, DOI: 10.1161/jaha.114.001343.Peer-Reviewed Original ResearchConceptsACEI/ARB therapyAcute myocardial infarctionClass I indicationsARB therapyMyocardial infarctionMortality riskReceptor blockersAngiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor BlockersEnzyme inhibitors/angiotensin receptor blockersChina PEACE-Retrospective AMI StudyChinese AMI patientsClass IIa recommendationRates of therapyAbsence of contraindicationsAngiotensin receptor blockersHigher mortality riskCost-effective therapyIIa recommendationAMI patientsChina PatientRetrospective studyHigh riskPatterns of useChinese guidelinesPatients